Kiniksa Pharmaceuticals International, plc 8K

Kiniksa Pharmaceuticals reported strong Q2 2026 results with raised ARCALYST revenue guidance, positive KPL-387 Phase 2 data supporting an ongoing pivotal Phase 3 trial, continued pipeline progress, and maintained profitability and liquidity.

On July 28, 2026, Kiniksa Pharmaceuticals International, plc reported its second quarter 2026 financial results and provided an update on its portfolio, highlighting ARCALYST net product revenue of $243.6 million (approximately 55% year-over-year growth) and raising full-year 2026 ARCALYST net revenue guidance to $980–$995 million, while also announcing positive Phase 2 interval data for KPL-387 in recurrent pericarditis that supported selection of a 300 mg once-monthly subcutaneous dose for the pivotal Phase 3 PASTORALE trial, which is now enrolling and dosing patients. The company detailed expanded R&D investment, continued development of KPL-1161 with plans to initiate a Phase 1 trial by year-end 2026, reported Q2 2026 net income of $25.4 million and a cash balance of $525.9 million with no debt, and stated that it expects to remain cash flow positive on an annual basis under its current operating plan.

Filing Facts

CIK

1730430

Ticker

KNSA

Form

8K

Source Type

fda

Accession

0001730430-26-000031

Alert Tier

7